Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Condition:   Hepatocellular Carcinoma Interventions:   Drug: Anlotinib;   Device: TACE+RFA Sponsor:   Jinglong Chen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials